Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability.

Malaguarnera G, Bertino G, Chisari G, Motta M, Vecchio M, Vacante M, Caraci F, Greco C, Drago F, Nunnari G, Malaguarnera M.

BMC Psychiatry. 2016 Nov 15;16(1):398.

2.

Extracellular cGMP Modulates Learning Biphasically by Modulating Glycine Receptors, CaMKII and Glutamate-Nitric Oxide-cGMP Pathway.

Cabrera-Pastor A, Malaguarnera M, Taoro-Gonzalez L, Llansola M, Felipo V.

Sci Rep. 2016 Sep 16;6:33124. doi: 10.1038/srep33124.

3.

Hepatocellular carcinoma and the risk of occupational exposure.

Rapisarda V, Loreto C, Malaguarnera M, Ardiri A, Proiti M, Rigano G, Frazzetto E, Ruggeri MI, Malaguarnera G, Bertino N, Malaguarnera M, Catania VE, Di Carlo I, Toro A, Bertino E, Mangano D, Bertino G.

World J Hepatol. 2016 May 8;8(13):573-90. doi: 10.4254/wjh.v8.i13.573. Review.

4.

Single-Incision Laparoscopic Cholecystectomy: our experience and review of literature.

Zanghì G, Leanza V, Vecchio R, Malaguarnera M, Romano G, Rinzivillo NM, Catania V, Basile F.

G Chir. 2015 Nov-Dec;36(6):243-6. Review.

5.

Hyperammonemia induces glial activation, neuroinflammation and alters neurotransmitter receptors in hippocampus, impairing spatial learning: reversal by sulforaphane.

Hernández-Rabaza V, Cabrera-Pastor A, Taoro-González L, Malaguarnera M, Agustí A, Llansola M, Felipo V.

J Neuroinflammation. 2016 Feb 16;13:41. doi: 10.1186/s12974-016-0505-y.

6.

Chronic hepatitis C: This and the new era of treatment.

Bertino G, Ardiri A, Proiti M, Rigano G, Frazzetto E, Demma S, Ruggeri MI, Scuderi L, Malaguarnera G, Bertino N, Rapisarda V, Di Carlo I, Toro A, Salomone F, Malaguarnera M, Bertino E, Malaguarnera M.

World J Hepatol. 2016 Jan 18;8(2):92-106. doi: 10.4254/wjh.v8.i2.92. Review.

7.

Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin.

Malaguarnera M, Motta M, Vacante M, Malaguarnera G, Caraci F, Nunnari G, Gagliano C, Greco C, Chisari G, Drago F, Bertino G.

Am J Transl Res. 2015 Nov 15;7(11):2510-8.

8.

Endozepine-4 levels are increased in hepatic coma.

Malaguarnera G, Vacante M, Drago F, Bertino G, Motta M, Giordano M, Malaguarnera M.

World J Gastroenterol. 2015 Aug 14;21(30):9103-10. doi: 10.3748/wjg.v21.i30.9103.

9.

The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies.

Bertino G, Demma S, Ardiri A, Proiti M, Mangia A, Gruttadauria S, Toro A, Di Carlo I, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M.

Biomed Res Int. 2015;2015:731469. doi: 10.1155/2015/731469. Review. Retraction in: BioMed Research International. Biomed Res Int. 2016;2016:2514067.

10.

Hepatocellular carcinoma markers in the omics era: the glycomic analysis.

Malaguarnera G, Bertino G, Vacante M, Malaguarnera M.

Hepatobiliary Surg Nutr. 2014 Dec;3(6):407-9. doi: 10.3978/j.issn.2304-3881.2014.07.04.

11.

Renal function and ultrasound imaging in elderly subjects.

Zanoli L, Romano G, Romano M, Rastelli S, Rapisarda F, Granata A, Fatuzzo P, Malaguarnera M, Castellino P.

ScientificWorldJournal. 2014;2014:830649. doi: 10.1155/2014/830649.

12.

Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives.

Malaguarnera G, Giordano M, Nunnari G, Bertino G, Malaguarnera M.

World J Gastroenterol. 2014 Nov 28;20(44):16639-48. doi: 10.3748/wjg.v20.i44.16639. Review.

13.

Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies.

Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M, Di Carlo I.

Biomed Res Int. 2014;2014:203693. doi: 10.1155/2014/203693. Review.

14.

Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial.

Malaguarnera G, Pennisi M, Gagliano C, Vacante M, Malaguarnera M, Salomone S, Drago F, Bertino G, Caraci F, Nunnari G, Malaguarnera M.

Hepat Mon. 2014 May 5;14(5):e11608. doi: 10.5812/hepatmon.11608.

15.

Omega-3 fatty acids and depression: scientific evidence and biological mechanisms.

Grosso G, Galvano F, Marventano S, Malaguarnera M, Bucolo C, Drago F, Caraci F.

Oxid Med Cell Longev. 2014;2014:313570. doi: 10.1155/2014/313570. Review.

16.

A new sampling method for spleen stiffness measurement based on quantitative acoustic radiation force impulse elastography for noninvasive assessment of esophageal varices in newly diagnosed HCV-related cirrhosis.

Rizzo L, Attanasio M, Pinzone MR, Berretta M, Malaguarnera M, Morra A, L'Abbate L, Balestreri L, Nunnari G, Cacopardo B.

Biomed Res Int. 2014;2014:365982. doi: 10.1155/2014/365982.

17.

Neurotoxicity of acrylamide in exposed workers.

Pennisi M, Malaguarnera G, Puglisi V, Vinciguerra L, Vacante M, Malaguarnera M.

Int J Environ Res Public Health. 2013 Aug 27;10(9):3843-54. doi: 10.3390/ijerph10093843. Review.

18.

Lipoprotein(a) serum levels in diabetic patients with retinopathy.

Malaguarnera G, Gagliano C, Bucolo C, Vacante M, Salomone S, Malaguarnera M, Leonardi DG, Motta M, Drago F, Avitabile T.

Biomed Res Int. 2013;2013:943505. doi: 10.1155/2013/943505.

19.

Lipoprotein(a) in cardiovascular diseases.

Malaguarnera M, Vacante M, Russo C, Malaguarnera G, Antic T, Malaguarnera L, Bella R, Pennisi G, Galvano F, Frigiola A.

Biomed Res Int. 2013;2013:650989. doi: 10.1155/2013/650989. Review.

20.

Serum markers of intrahepatic cholangiocarcinoma.

Malaguarnera G, Paladina I, Giordano M, Malaguarnera M, Bertino G, Berretta M.

Dis Markers. 2013;34(4):219-28. doi: 10.3233/DMA-130964. Review.

Items per page

Supplemental Content

Loading ...
Support Center